Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02080078
Title A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors AHS Cancer Control Alberta, Cross Cancer Institute

lung non-small cell carcinoma

Advanced Solid Tumor


Erlotinib + Theophylline

Age Groups: adult
Covered Countries CAN

No variant requirements are available.